According to a Reuters article on the Medscape Oncology web site, the health insurance giant Aetna is to cover costs for sipuleucel-T in a larger number of men with metastatic, castation-resistant prostate cancer (mCRPC).
According to Reuters, Aetna now says that it will cover costs of treatment with sipuleucel-T therapy for with mCRPC who do not respond or have stopped responding to androgen deprivation therapy and whose disease has spread to the lungs or the brain. Such men were not previously eligible for treatment with sipuleucel-T according to Aetna’s coverage guidance. We cannot find any such statement on the Aetna web site, but we consider Rueters to be a highly reliable source for this type of information.
It should be noted, however, that Aetna still will not cover costs of such therapy for those men whose disease has spread to the liver.
Filed under: Uncategorized
Search for new and
ongoing trials on the
CTAG PCa web site
